61 related articles for article (PubMed ID: 30006409)
1. PABPN1 loss-of-function causes APA-shift in oculopharyngeal muscular dystrophy.
Shademan M; Mei H; van Engelen B; Ariyurek Y; Kloet S; Raz V
HGG Adv; 2024 Apr; 5(2):100269. PubMed ID: 38213032
[TBL] [Abstract][Full Text] [Related]
2. Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1.
Malerba A; Klein P; Lu-Nguyen N; Cappellari O; Strings-Ufombah V; Harbaran S; Roelvink P; Suhy D; Trollet C; Dickson G
Hum Mol Genet; 2019 Oct; 28(19):3301-3308. PubMed ID: 31294444
[TBL] [Abstract][Full Text] [Related]
3. Recent Progress in Oculopharyngeal Muscular Dystrophy.
Yamashita S
J Clin Med; 2021 Mar; 10(7):. PubMed ID: 33805441
[TBL] [Abstract][Full Text] [Related]
4. Chromatin-modifying drugs and metabolites in cell fate control.
Yao Z; Chen Y; Cao W; Shyh-Chang N
Cell Prolif; 2020 Nov; 53(11):e12898. PubMed ID: 32979011
[TBL] [Abstract][Full Text] [Related]
5. RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement.
Abu-Baker A; Kharma N; Perreault J; Grant A; Shekarabi M; Maios C; Dona M; Neri C; Dion PA; Parker A; Varin L; Rouleau GA
Mol Ther Nucleic Acids; 2019 Apr; 15():12-25. PubMed ID: 30831428
[TBL] [Abstract][Full Text] [Related]
6. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy.
Fan X; Rouleau GA
Can J Neurol Sci; 2003 Feb; 30(1):8-14. PubMed ID: 12619777
[TBL] [Abstract][Full Text] [Related]
7. Oculopharyngeal muscular dystrophy: a polyalanine myopathy.
Brais B
Curr Neurol Neurosci Rep; 2009 Jan; 9(1):76-82. PubMed ID: 19080757
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid is protective in cellular and worm models of oculopharyngeal muscular dystrophy.
Abu-Baker A; Parker A; Ramalingam S; Laganiere J; Brais B; Neri C; Dion P; Rouleau G
Neurology; 2018 Aug; 91(6):e551-e561. PubMed ID: 30006409
[TBL] [Abstract][Full Text] [Related]
9. Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1.
García-Castañeda M; Vega AV; Rodríguez R; Montiel-Jaen MG; Cisneros B; Zarain-Herzberg A; Avila G
J Physiol; 2017 Jul; 595(13):4167-4187. PubMed ID: 28303574
[TBL] [Abstract][Full Text] [Related]
10. Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.
Vest KE; Phillips BL; Banerjee A; Apponi LH; Dammer EB; Xu W; Zheng D; Yu J; Tian B; Pavlath GK; Corbett AH
Hum Mol Genet; 2017 Sep; 26(17):3235-3252. PubMed ID: 28575395
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.
Doki T; Yamashita S; Wei FY; Hara K; Yamamoto T; Zhang Z; Zhang X; Tawara N; Hino H; Uyama E; Kurashige T; Maruyama H; Tomizawa K; Ando Y
Lab Invest; 2019 Nov; 99(11):1728-1740. PubMed ID: 30894671
[TBL] [Abstract][Full Text] [Related]
12. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.
Chartier A; Benoit B; Simonelig M
EMBO J; 2006 May; 25(10):2253-62. PubMed ID: 16642034
[TBL] [Abstract][Full Text] [Related]
13. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.
Roth F; Dhiab J; Boulinguiez A; Mouigni HR; Lassche S; Negroni E; Muraine L; Marhic A; Oliver A; Lainé J; Rouche A; O'Ferrall EK; van Engelen B; Ottenheijm C; Greif H; Blumen S; Lacau St Guily J; Perie S; Butler-Browne G; Mouly V; Trollet C
Acta Neuropathol; 2022 Dec; 144(6):1157-1170. PubMed ID: 36197469
[TBL] [Abstract][Full Text] [Related]
14. Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/β-catenin pathway.
Abu-Baker A; Laganiere J; Gaudet R; Rochefort D; Brais B; Neri C; Dion PA; Rouleau GA
Cell Death Dis; 2013 Oct; 4(10):e821. PubMed ID: 24091664
[TBL] [Abstract][Full Text] [Related]
15. Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study.
Périé S; Trollet C; Mouly V; Vanneaux V; Mamchaoui K; Bouazza B; Marolleau JP; Laforêt P; Chapon F; Eymard B; Butler-Browne G; Larghero J; St Guily JL
Mol Ther; 2014 Jan; 22(1):219-25. PubMed ID: 23831596
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
